Estradiol-PGC-1 signaling in mitochondrial health: Implications for perimenopause and cardiovascular disease.
- 1Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
Cardiovascular disease (CVD) is the leading cause of death in aging women. While CVD etiology is multifactorial, mitochondrial dysfunction, characterized by reduced content, impaired energy production, and increased oxidative stress, is an underlying contributor. These impairments reduce the ability of the heart and vasculature to support peripheral tissues. Estradiol, a key sex hormone with widespread physiological effects, supports mitochondrial function, lipid oxidation, vascular endothelial cell and smooth muscle function, and redox balance, contributing to its cardioprotective effects in women. Perimenopause is marked by hormonal variability and an overall decline in estradiol concentrations that may compromise mitochondrial quality and vascular function, increasing CVD risk. Mitochondrial quality and maintenance are largely controlled by the peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family of transcriptional coactivators. Impairments in PGC-1 isoform expression have been linked to cardiovascular and metabolic decline and may be exacerbated by estradiol loss during the menopause transition. However, the mechanisms by which estradiol signaling regulates PGC-1 isoforms, and how this interaction contributes to mitochondrial dysfunction and CVD development following menopause, have not been comprehensively described. Thus, this review aims to highlight current evidence on the individual and overlapping roles of estradiol and PGC-1 isoforms and examine how their interaction may contribute to the development of CVD following menopause.
Related
- Sex Differences in Mitochondrial Function: Endocrine Regulation, Immunometabolic Signaling, and Implications for Health and Disease
- PACE4 Regulates Apoptosis in Human Prostate Cancer Cells via Endoplasmic Reticulum Stress and Mitochondrial Signaling Pathways [Retraction].
- Primary cilia disruption reprograms extracellular vesicle signaling in endothelial dysfunction and cardiovascular disease
- Mechanism of luteolin in treating chronic heart failure by regulating HIF-1 signaling pathway-mediated mitochondrial damage to inhibit cardiomyocyte apoptosis
- Yeast Mitochondrial Escape 1-Like as a Mitochondrial Gatekeeper in Aging-Related Cardiovascular Disease
BibTeX
@article{parten2026estradiolpgc1,
title = {{Estradiol-PGC-1 signaling in mitochondrial health: Implications for perimenopause and cardiovascular disease.}},
author = {Alyssa L Parten and Glenn C Rowe},
journal = {Physiological reports},
year = {2026},
month = oct,
doi = {10.14814/phy2.71155},
url = {https://europepmc.org/article/MED/42908178},
note = {CC BY},
}
RIS
TY - JOUR
TI - Estradiol-PGC-1 signaling in mitochondrial health: Implications for perimenopause and cardiovascular disease.
AU - Alyssa L Parten
AU - Glenn C Rowe
PY - 2026
DA - 2026/10/01
JO - Physiological reports
DO - 10.14814/phy2.71155
UR - https://europepmc.org/article/MED/42908178
AB - Cardiovascular disease (CVD) is the leading cause of death in aging women. While CVD etiology is multifactorial, mitochondrial dysfunction, characterized by reduced content, impaired energy production, and increased oxidative stress, is an underlying contributor. These impairments reduce the ability of the heart and vasculature to support peripheral tissues. Estradiol, a key sex hormone with widespread physiological effects, supports mitochondrial function, lipid oxidation, vascular endothelial cell and smooth muscle function, and redox balance, contributing to its cardioprotective effects in women. Perimenopause is marked by hormonal variability and an overall decline in estradiol concentrations that may compromise mitochondrial quality and vascular function, increasing CVD risk. Mitochondrial quality and maintenance are largely controlled by the peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family of transcriptional coactivators. Impairments in PGC-1 isoform expression have been linked to cardiovascular and metabolic decline and may be exacerbated by estradiol loss during the menopause transition. However, the mechanisms by which estradiol signaling regulates PGC-1 isoforms, and how this interaction contributes to mitochondrial dysfunction and CVD development following menopause, have not been comprehensively described. Thus, this review aims to highlight current evidence on the individual and overlapping roles of estradiol and PGC-1 isoforms and examine how their interaction may contribute to the development of CVD following menopause.
SN - 2051-817X
ER -